<DOC>
	<DOC>NCT02083289</DOC>
	<brief_summary>The primary objectives of this study are to compare the safety, tolerability, and mean change from baseline in diurnal intraocular pressure (IOP) of ONO-9054 30 µg/mL (0.003%) to latanoprost 0.005% following ocular instillation once every evening for 28 days.</brief_summary>
	<brief_title>A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Glaucoma, Open-Angle</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>Male or female aged 1885 (inclusive) with confirmed diagnosis of OHT or OAG Confirmed diagnosis of bilateral OHT or mild to moderate chronic OAG Able to undergo washout of all ocular drugs An IOP ≥ 24 mmHg at 8:00 AM and ≥ 21 mmHg at 10:00 AM in at least 1 eye; but &lt; 36 mmHg in both eyes at both Day 5 and Day 1 Central corneal thickness 500620 µm at screening and Day 5 in both eyes Best corrected visual acuity (BCVA) of +0.7 Log Mar or better Any history of severe ocular trauma in either eye at any time History of angle closure or ocular laser surgery within the past 3 months or any refractive surgery procedure within the past 6 months of Screening Visit in the study eye(s) Cataracts that prevent observation or photography of the fundus in either eye</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>ONO-9054</keyword>
	<keyword>ocular hypertension (OHT)</keyword>
	<keyword>Open angle-glaucoma (OAG)</keyword>
	<keyword>Glaucoma</keyword>
	<keyword>Eye Diseases</keyword>
	<keyword>Mild to moderate</keyword>
</DOC>